Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom
HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea
376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland
HMP
Hengrui Pharma Logo
China
600276
HERON THERAPEUTICS, INC. /DE/ Logo
Develops and commercializes therapies for acute care and oncology to manage pain and nausea.
United States of America
HRTX
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea
106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom
HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan
4530
HK inno.N Corporation Logo
South Korea
195940
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea
187420

Talk to a Data Expert

Have a question? We'll get back to you promptly.